Ozempic and Wegovy Price Drop 2027: What It Means for Patients

On February 24, 2026, Novo Nordisk announced something that would have seemed unlikely two years ago: a major price cut on its entire semaglutide portfolio. Wegovy, Ozempic, and Rybelsus are all dropping to $675 per month effective January 1, 2027.

For Wegovy, that is roughly a 50% reduction from the current list price of approximately $1,349/month. For Ozempic, about 35%.

This is one of the most significant access developments in GLP-1 medication history. Here is what you need to know, what it means for your costs, and what you can do right now.

What exactly was announced?

Novo Nordisk confirmed that effective January 1, 2027:

The company framed this as a move to improve access, particularly for patients whose out-of-pocket costs are directly linked to the list price — such as those with high-deductible health plans, co-insurance arrangements, or no insurance coverage.

This is a list price change, not a negotiated price change. List price is the starting point from which all other pricing (insurance discounts, rebates, self-pay) is calculated.

Why is this happening now?

This did not happen by accident. Several converging pressures made a price cut inevitable.

Competition from Eli Lilly and new entrants

Orforglipron, Eli Lilly's once-daily oral GLP-1 pill with no injection and no food restrictions, is in FDA review as of early 2026. It is widely expected to launch at a lower price point than injectable semaglutide — and its ease of use makes it a direct competitive threat.

Tirzepatide (Zepbound, Mounjaro) from Eli Lilly already matches or exceeds semaglutide's weight loss efficacy and is gaining market share. Wegovy and Ozempic needed to compete on price.

Political and public pressure on drug pricing

GLP-1 medications have been the subject of significant political scrutiny. Congressional hearings on drug pricing, Medicare negotiation under the Inflation Reduction Act, and ongoing media coverage of the affordability crisis created pressure that Novo Nordisk could not ignore.

A proactive price cut allows Novo Nordisk to manage that narrative on its own terms.

The compounded semaglutide challenge

For two years, millions of Americans accessed compounded semaglutide at $99–$250/month through telehealth platforms like Hims & Hers, Ro, Found, and direct compounding pharmacies. Novo Nordisk fiercely opposed this, arguing it was unsafe and illegal.

Now that the FDA has resolved the semaglutide shortage — which was the regulatory basis for compounding exemptions — that market is changing. As compounding closes, Novo Nordisk needs a price that is competitive enough to win back those patients. $675/month is a direct response to the $99–$250 compounding price range.

Expanding the realistic patient base

Obesity affects over 100 million Americans and approximately 650 million adults globally. At $1,349/month, the realistic patient base was largely limited to insured patients with good coverage or the wealthy. At $675/month, a substantially larger portion of the population can access treatment.

From a business perspective, selling to twice as many patients at half the price is a similar revenue calculation — but dramatically increases social impact.

Who benefits most from the 2027 price cut?

The list price reduction is not a universal win. Its impact depends heavily on how you currently pay.

Biggest beneficiaries

Patients with high-deductible health plans (HDHPs) If your plan calculates your deductible-phase costs as a percentage of list price, a 50% list price reduction directly translates to lower out-of-pocket costs for you.

Patients with co-insurance plans If your plan charges you a percentage of the drug cost (e.g. 20% co-insurance), a lower list price directly reduces your share.

Cash-pay patients Anyone paying completely out of pocket gets the full benefit of the reduction.

Medicare Part D patients Under the Inflation Reduction Act and evolving Part D rules, list price increasingly affects Medicare beneficiary costs. A lower list price will benefit many Medicare Wegovy and Ozempic users.

Less direct benefit

Patients with fixed-dollar insurance copays If your plan charges a flat $40/month copay regardless of the drug's price, the list price change does not affect your immediate costs. It may, however, affect your plan's coverage decisions and long-term formulary positioning.

Patients on manufacturer coupons If you are currently using Novo Nordisk's $99 or $25 coupon programmes, your price is already below the new list price.

What can you do right now, before 2027?

You do not have to wait until January 2027 to reduce your cost. Several options are available today.

NovoCare Pharmacy (Novo Nordisk direct)

Novo Nordisk's own direct pharmacy, novocare.com, offers self-pay pricing for Wegovy at $499/month — no insurance required. This is available now.

This price is already below the new 2027 list price and represents the most direct route from Novo Nordisk to patient for those without useful coverage.

Hims & Hers and major telehealth platforms

Following the March 9, 2026 agreement between Novo Nordisk and Hims & Hers, the platform now offers branded Wegovy at the same NovoCare self-pay prices. Similar arrangements have been announced or are expected with Ro, Found, and other telehealth platforms.

These platforms also provide clinical consultation, prescription management, and support — making them a convenient full-service option for many patients.

Insurance prior authorisation

Many plans now cover Wegovy, especially following:

• The 2023 FDA approval of semaglutide for cardiovascular risk reduction (SELECT trial data)
• Expanding employer wellness benefits that include obesity drugs
• State and federal coverage mandates

If your plan denied coverage previously, it may be worth reapplying. Updated clinical documentation from your doctor showing BMI, weight-related conditions, and treatment history strengthens the case for approval.

LillyDirect (for Zepbound and Mounjaro)

If you are considering switching to tirzepatide, Eli Lilly's LillyDirect platform offers Zepbound single-dose vials at competitive self-pay pricing. For patients whose clinical profile makes tirzepatide a good fit, this is worth comparing to the Wegovy self-pay options.

Patient assistance programmes

Both Novo Nordisk and Eli Lilly offer formal patient assistance programmes for people who genuinely cannot afford medication. Eligibility is income-based. Visit the manufacturer's website or ask your doctor's office for help with the application.

What does this mean for the broader GLP-1 market?

The Novo Nordisk price cut creates competitive pressure across the entire space.

Eli Lilly: Has not yet announced equivalent price cuts for tirzepatide. But with Wegovy dropping to $675/month, Zepbound and Mounjaro will face pricing pressure. A response from Lilly — either a price reduction or expanded direct pricing programmes — is widely anticipated.

Orforglipron: When it launches (expected 2026), its pricing will define the new floor for oral GLP-1 options. If it launches below $675/month — which analysts expect — it will reshape the market again.

Generic semaglutide: Patent expiry for semaglutide is several years away, but when it arrives, prices will drop dramatically. The current price cuts can be seen as Novo Nordisk positioning itself ahead of that inevitable competition.

International markets: The $675/month US price is still dramatically higher than semaglutide pricing in most other countries. In India, generic semaglutide (Obeda, Semaglyn, Sematrinity) is available at a fraction of this cost. Global pricing convergence is a longer-term story.

Should you wait until 2027?

For most patients, no. If you need medication now and a self-pay option like NovoCare's $499/month is accessible, waiting a year to save an additional $174/month is not clinically sensible.

If cost is the main barrier and you are not in urgent clinical need, and you have no insurance coverage options, you may choose to wait for the January 2027 cut. In that window, it is worth reviewing whether your insurance situation has changed — coverage decisions often improve as list prices fall and insurer risk calculations change.

If you are currently on compounded semaglutide and that option is closing for you, the NovoCare self-pay route is the most direct path to continuity of care.

Final takeaway

Wegovy and Ozempic are dropping to $675/month list price effective January 1, 2027 — roughly half the current Wegovy price and a significant step toward making GLP-1 therapy accessible to a much larger population.

Patients whose costs are directly tied to list price will see the most immediate benefit. In the meantime, self-pay options through NovoCare and major telehealth platforms already offer prices in or near this range today.

If access to GLP-1 medication has been a barrier, the landscape is improving significantly.

Consult your healthcare provider about which medication and payment option is right for your situation.

Related Articles

• Obeda Price in India (2026): Full Cost Breakdown
• Is Obeda 60% Cheaper Than Ozempic?
• Compounded Semaglutide Ending: What to Do

Sources

• Novo Nordisk price reduction announcement, February 24, 2026: drugs.com
• Wegovy FDA approval history: drugs.com/history/wegovy.html
• Ozempic prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• Wegovy prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf